Samsung BioLogics acquires GlaxoSmithKline's US plant for $280 million.

Samsung Biologics, a subsidiary of the Samsung Group, announced on Wednesday that it has spent 280 million dollars to acquire a factory of the British pharmaceutical giant GlaxoSmithKline in the United States. Samsung Biologics stated that this factory, located in Rockville, Maryland, has a production capacity of 60,000 liters of active pharmaceutical ingredients, bringing the total capacity of the company to 845,000 liters.